corner
Healthy Skepticism
Join us to help reduce harm from misleading health information.
Increase font size   Decrease font size   Print-friendly view   Print
Register Log in

Healthy Skepticism Library

Items published in 2013

There are 69 items in the Healthy Skepticism Library that were published in 2013.

Page 1 of 1 pages

HSL20592
Wegwarth O, Gigerenzer G
Overdiagnosis and Overtreatment: Evaluation of What Physicians Tell Their Patients About Screening Harms
JAMA Internal Med 2013 Dec; 173:(22):2086-2087
http://archinte.jamanetwork.com/article.aspx?articleID=1754987

HSL20591
Schwitzer G
When doctors don’t discuss harms of screening tests with patients
Health New Review.org 2013 Oct 22
http://www.healthnewsreview.org/2013/10/when-doctors-dont-discuss-harms-of-screening-tests-with-patients/

HSL20593
Unreliable research: Trouble at the lab
The Economist 2013 Oct 19

HSL20585
Ubel PA, Abernethy AP, Zafar SY
Full Disclosure - Out-of-Pocket Costs as Side Effects
NEJM 2013 Oct 17; 369:
http://www.nejm.org/doi/full/10.1056/NEJMp1306826

HSL20586
Wen L
What Do You Know About Your Doctor?
Psychology Today 2013 Oct 15
http://www.psychologytoday.com/blog/the-doctor-is-listening/201310/what-do-you-know-about-your-doctor

HSL20587
Blumer C
Ethical Triage For Doctors
The Globe and Mail 2013 Oct 15
http://www.theglobalmail.org/blog/ethical-triage-for-doctors/710/

HSL20588
Bertens LCM, Broekhuizen BDL, Naaktgeboren CA, Rutten FH, Hoes AW, van Mourik Y, Moons KGM, Reitsma JB
Use of Expert Panels to Define the Reference Standard in Diagnostic Research: A Systematic Review of Published Methods and Reporting
PLoS Med 2013 Oct 15; 10:(10):
http://www.plosmedicine.org/article/info:doi/10.1371/journal.pmed.1001531

HSL20589
Blumer C
Medical Ethics Under The Knife
The Global Mail 2013 Oct 9
http://www.theglobalmail.org/feature/medical-ethics-under-the-knife/707/

HSL20590
Arie S
Doctors’ groups are criticised for endorsing pro-industry guidelines
BMJ 2013 Oct 9; 347:
http://www.bmj.com/content/347/bmj.f6066

HSL20584
Taylor L
Serious side-effects warnings can increase drug sales: study
PharmaTimes 2013 Sep 24
http://www.pharmatimes.com/Article/13-09-24/Serious_side-effects_warnings_can_increase_drug_sales_study.aspx

HSL20583
Bowie C
Sales reps struggling with the new NHS environment
Pharma Times 2013 Aug 30
http://www.pharmatimes.com/Article/13-08-30/Sales_reps_struggling_with_the_new_NHS_environment.aspx

HSL20581
Burns M
Report profiles cardiologists for market insights
Pharmalive 2013 Aug 29
http://www.pharmalive.com/report-profiles-cardiologists-for-market-insights

HSL20580
Moynihan RN, Cooke GPE, Doust JA, Bero L, Hill S, Glasziou PP
Expanding Disease Definitions in Guidelines and Expert Panel Ties to Industry: A Cross-sectional Study of Common Conditions in the United States
PLoS Med 2013 Aug 13;
http://www.plosmedicine.org/article/info:doi/10.1371/journal.pmed.1001500

HSL20578
Cavicchi V
Defining the Audience: Customer-Centric Sales Strategies and Physician Segmentation
Cutting Edge Info 2013 July 24
http://www.cuttingedgeinfo.com/2013/defining-audience-customer-centric-sales-strategies-physician-segmentation/

HSL20575
Fern Tay H
Chinese police accuse GlaxoSmithKline of artificially inflating cost of medicine
PM : ABC Radio National 2013 July 180
http://www.abc.net.au/pm/content/2013/s3806244.htm

HSL20574
Yan A, Han Shih T
Shanghai travel agent's revenue surge led to arrests in GSK bribery case
South China Post 2013 July 16
http://www.scmp.com/news/china/article/1283207/glaxosmithkline-suspects-drug-bribery-probe-identified

HSL20573
Trans-Pacific trade agreement could choke off patient access to affordable generic medicines
Medicines Sans Frontiers 2013 July 15
http://www.msfaccess.org/about-us/media-room/press-releases/trans-pacific-trade-agreement-could-choke-patient-access

HSL20577
Nagarajan R
The patient doctor
The Times of India 2013 July 6
http://www.timescrest.com/coverstory/the-patient-doctor-10659

HSL20571
Burns M
Study unearths ‘surprising’ findings on doctors’ good publication practice views
Pharmalive 2013 Jun 26
http://www.pharmalive.com/study-unearths-‘surprising’-findings-on-doctors’-good-publication-practice-views

HSL20579
Wise J
Novartis found to be in breach of code over drug brochure
BMJ 2013 Jun 20; 346:
http://www.bmj.com/content/346/bmj.f4061

HSL20568
Davies E
Flu hype and pharma failures: patients deserve better
BMJ 2013 May 24; 346:
http://www.bmj.com/content/346/bmj.f3422

HSL20561
Eban K
The latest to claim fraud at generic Lipitor maker Ranbaxy: Its owners
CNN Money 2013 May 23
http://features.blogs.fortune.cnn.com/2013/05/23/ranbaxy-lipitor-fraud/

HSL20562
Harvey K, Voevodin M
Regulations around food-medicine products fail to protect consumers
The Conversation 2013 May 21
https://theconversation.com/regulations-around-food-medicine-products-fail-to-protect-consumers-14360

HSL20570
Davies E
Can Big Pharma put patients first?
BMJ 2013 May 21; 346:
http://www.bmj.com/content/346/bmj.f3285

HSL20560
Govt to regulate rates of 652 medicines; prices set to fall
Economic Times 2013 May 17
http://articles.economictimes.indiatimes.com/2013-05-17/news/39336744_1_essential-drugs-price-control-indian-pharmaceutical-alliance

HSL20569
Doshi P
Influenza: marketing vaccine by marketing disease
BMJ 2013 May 16; 346:
http://www.bmj.com/content/346/bmj.f3037

HSL20559
Tiefer L, Witczak K, Heath I
A call to challenge the 'Selling of Sickness'
BMJ 2013 May 14; 346:f2809 doi: http://dx.doi.org/10.1136/bmj.f2809
http://www.bmj.com/content/346/bmj.f2809

HSL20563
Corderoy A
Most pills and potions fail the test
The Sydney Morning Herald 2013 May 12
http://www.smh.com.au/national/health/most-pills-and-potions-fail-the-test-20130511-2jeji.html

HSL20564
Corderoy A
War of words on potions and pills continues
The Sydney Morning Herald 2013 May 12
http://www.smh.com.au/national/health/war-of-words-on-potions-and-pills-continues-20130511-2jely.html

HSL20558
Rome E
Big Pharma CEOs Rake in $1.57 Billion in Pay
The Huffington Post 2013 May 8
http://www.huffingtonpost.com/ethan-rome/big-pharma-ceo-pay_b_3236641.html

HSL20565
McCredie J
Jane McCredie: A drop of credibility
MJA InSight 2013 May 6;
https://www.mja.com.au/insight/2013/16/jane-mccredie-drop-credibility

HSL20566
Ed.
Exorbitant Prices for Leukemia Drugs
The New York Times 2013 May 1
http://www.nytimes.com/2013/05/02/opinion/exorbitant-prices-for-cancer-drugs.html?_r=0

HSL20551
How Big Pharma Is Killing Americans
Truthout 2013 Apr 29
http://truth-out.org/opinion/item/16071-how-big-pharma-is-killing-americans

HSL20531
Rosenberg M
6 New Ways Big Pharma Is Scheming to Make Billions at the Expense of Your Health
Alternet 2013 Apr 25
http://www.alternet.org/personal-health/6-new-ways-big-pharma-scheming-make-billions-expense-your-health?paging=off

HSL20532
J.D. Power study shows physicians still see reps as main influence
Pharmalive 2013 Apr 25
http://www.pharmalive.com/jd-power-and-associates-reports-that-relationship-marketing-still-matters-in-oncology-pharma-sales

HSL20530
US govt sues Novartis for health care fraud
The Indian Express 2013 Apr 24
http://m.indianexpress.com/news/us-govt-sues-novartis-for-health-care-fraud/1106948/

HSL20501
Indian Supreme Court Delivers Verdict in Novartis Case
Medicines Sans Frontiers 2013 Apr 1
http://www.msfaccess.org/about-us/media-room/press-releases/indian-supreme-court-delivers-verdict-novartis-case

HSL20495
Ed.
Getting Closer to a Fully Correctable and Connected Research Literature
PLoS Med 2013 Mar 26; 10:(3):
http://www.plosmedicine.org/article/info%3Adoi%2F10.1371%2Fjournal.pmed.1001408?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+plosmedicine%2FNewArticles+%28Ambra+-+Medicine+New+Articles%29

HSL20496
Ana J, KoehlmoosT, Smith R, Yan LL
Research Misconduct in Low- and Middle-Income Countries
PLoS Med 2013 Mar 26; 10:(3):
http://www.plosmedicine.org/article/info%3Adoi%2F10.1371%2Fjournal.pmed.1001315

HSL20497
Resnik DB, Master Z
Policies and Initiatives Aimed at Addressing Research Misconduct in High-Income Countries
PLoS Med 2013 Mar 26; 10:(3):
http://www.plosmedicine.org/article/info%3Adoi%2F10.1371%2Fjournal.pmed.1001406?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+plosmedicine%2FNewArticles+%28Ambra+-+Medicine+New+Articles%29

HSL20498
Svensson S, Menkes DB, Lexchin J
Surrogate Outcomes in Clinical Trials: A Cautionary Tale
JAMA 2013 Mar 25; (1-2 ):
http://archinte.jamanetwork.com/article.aspx?articleid=1672283

HSL20493
Sharp C
Key Opinion Leaders – A Fast and Furious Approach to Brand Recognition
eyeforpharma 2013 Mar 21
http://social.eyeforpharma.com/sales-marketing/key-opinion-leaders-mclaren-content-marketing-barcelona

HSL20462
Brauser D
Psychiatrists Top List of Big Pharma Payments Again
Medscape 2013 Mar 14;
http://www.medscape.com/viewarticle/780835

HSL20461
Kmietowicz Z
BMA follows Lancet in quitting group on collaboration between doctors and drug industry
BMJ 2013 Mar 8; 346:
http://dx.doi.org/10.1136/bmj.f1574

HSL20455
'Bayer’s Tonic' still on the Market
Coalition against Bayer Dangers 2013 Mar 5
www.CBGnetwork.org

HSL20458
Bramwell N
TGA reform delays slammed
Medical Observer 2013 Mar 5
http://www.medicalobserver.com.au/news/tga-reform-delays-slammed

HSL20492
Wood M
Sales Excellence in the Pharma Industry: An Interview with Hoffmann-La Roche’s Michael van Olm
eyeforpharma 2013 Mar 4
http://social.eyeforpharma.com/sales-marketing/sales-excellence-pharma-roche-michael-van-olm-interview

HSL20456
Cymbalta still tops in U.S. drug promotion list
Med Ad News 2013 Feb 28
http://blog.medadnews.com/index.php/2013/02/28/cymbalta-still-tops-in-u-s-drug-promotion-list/

HSL20457
Kaye B
Senate bill to ban pharma freebies
Medical Observer 2013 Feb 28
http://www.medicalobserver.com.au/news/senate-bill-to-ban-pharma-freebies

HSL20460
Blumer C, Seccombe M
Who’s Your Doctor Dining With? (And Why You Should Care)
The Global Mail 2013 Feb 28
http://powerhouse.theglobalmail.org/whos-your-doctor-dining-with-and-why-you-should-care/

HSL20459
Pirri C
Embracing CAM
MJA InSight 2013 Feb 25
http://www.mjainsight.com.au/view?post=carlo-pirri-embracing-cam&post_id=12270&cat=comment&mo=1

HSL20470
Burns M
Manhattan Research: Pharma widens target to new decision makers
Med Ad News 2013 Feb 11
http://blog.medadnews.com/index.php/2013/02/11/pharma-widens-target-to-new-decision-makers/

HSL20452
Kmietowicz Z
GSK backs campaign for disclosure of trial data
BMJ 2013 Feb 7; 346:
http://www.bmj.com/content/346/bmj.f819

HSL20453
Roehr B
Drug companies will have to report all payments to US doctors from March 2014
BMJ 2013 Feb 7; 346:
http://www.bmj.com/content/346/bmj.f826

HSL20451
Davis C
Is there a cure for corporate crime in the drug industry?
BMJ 2013 Feb 6; 346:
http://www.bmj.com/content/346/bmj.f755

HSL20454
Tucker ME
Drug companies lobby against generic versions of biologics
BMJ 2013 Feb 4; 346:
http://www.bmj.com/content/346/bmj.f740

HSL20450
Horton R
Offline: Falling out with pharma
The Lancet 2013 Feb 2; 381:(9864):358
http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2813%2960139-7/fulltext

HSL20449
Kanter J, Thomas K
European Officials Say Drug Makers Paid to Delay Generic Version
The New York Times 2013 Jan 31
http://www.nytimes.com/2013/02/01/business/global/eu-says-drug-makers-paid-to-delay-generic-version.html?smid=tw-nytimeshealth&seid=auto&_r=1&

HSL20481
Ed.
Getting More Generous with the Truth: Clinical Trial Reporting in 2013 and Beyond
PLoS Med 2013 Jan 29; 10:(1):
http://www.plosmedicine.org/article/info%3Adoi%2F10.1371%2Fjournal.pmed.1001379

HSL20482
Vedula SS, Li T, Dickersin K
Differences in Reporting of Analyses in Internal Company Documents Versus Published Trial Reports: Comparisons in Industry-Sponsored Trials in Off-Label Uses of Gabapentin
PLoS Med 2013 Jan 29; 10:(1):
http://www.plosmedicine.org/article/info%3Adoi%2F10.1371%2Fjournal.pmed.1001378

HSL20448
Doherty B
Drug companies 'using Indians as guinea pigs'
The Sydney Morning Herald 2013 Jan 27
http://www.smh.com.au/world/drug-companies-using-indians-as-guinea-pigs-20130126-2dduh.html?skin=text-only

HSL20447
Entry prices for new medications fall 35%
brasil.gov.br 2013 Jan 22
http://www.brasil.gov.br/news/history/2013/01/22/entry-prices-for-new-medications-fall-35/newsitem_view?set_language=en

HSL20471
Duijnhoven RG, Straus SMJM, Raine JM, de Boer A, Hoes AW, De Bruin ML
Number of Patients Studied Prior to Approval of New Medicines: A Database Analysis
PLoS Med 2013;
http://www.plosmedicine.org/article/info:doi/10.1371/journal.pmed.1001407

HSL20542
Lopert R, Gleeson D
The High Price of “Free” Trade: U.S. Trade Agreements and Access to Medicines
The Journal of Law, Medicine & Ethics 2013; 41:(1):199–223
http://onlinelibrary.wiley.com/doi/10.1111/jlme.12014/abstract

HSL20572
Brougher J
Evergreening patents: The Indian Supreme Court rejects patenting of incremental improvements
Journal of Commerical Biotechnology 2013; 19:(3): doi: http://dx.doi.org/10.5912/jcb614
http://commercialbiotechnology.com/index.php/jcb/article/view/614

HSL20576
Light DW
Risky Drugs: Why The FDA Cannot Be Trusted
Journal of Law, Medicine and Ethics 2013;
http://www.ethics.harvard.edu/lab/blog/312-risky-drugs

HSL20506
Stamatakis E, Weiler R, Ioannidis JP.
Undue industry influences that distort healthcare research, strategy, expenditure and practice: a review.
Eur J Clin Invest 2013 25; doi: 10.1111/eci.12074. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/23521369

HSL20567
Burns M
Report: Access rates to physicians decline
Pharmalive 2013
http://www.pharmalive.com/report-access-rates-to-physicians-declines

HSL20582
Burns M
HxP seeks out ways to better arm salesforces
PharmaLive 2013
http://www.pharmalive.com/hxp-seeks-out-ways-to-better-arm-salesforces

Page 1 of 1 pages

 

  Healthy Skepticism on RSS   Healthy Skepticism on Facebook   Healthy Skepticism on Twitter

Please
Click to Register

(read more)

then
Click to Log in
for free access to more features of this website.

Forgot your username or password?

You are invited to
apply for membership
of Healthy Skepticism,
if you support our aims.

Pay a subscription

Support our work with a donation

Buy Healthy Skepticism T Shirts


If there is something you don't like, please tell us. If you like our work, please tell others.







Cases of wilful misrepresentation are a rarity in medical advertising. For every advertisement in which nonexistent doctors are called on to testify or deliberately irrelevant references are bunched up in [fine print], you will find a hundred or more whose greatest offenses are unquestioning enthusiasm and the skill to communicate it.

The best defence the physician can muster against this kind of advertising is a healthy skepticism and a willingness, not always apparent in the past, to do his homework. He must cultivate a flair for spotting the logical loophole, the invalid clinical trial, the unreliable or meaningless testimonial, the unneeded improvement and the unlikely claim. Above all, he must develop greater resistance to the lure of the fashionable and the new.
- Pierre R. Garai (advertising executive) 1963